Efficacy of Definitive Radiotherapy for Patients with Clinical Stage IIIB or IIIC Lung Adenocarcinoma and Epidermal Growth Factor Receptor (EGFR) Mutations Treated Using First- or Second-Generation EGFR Tyrosine Kinase Inhibitors
Table 4
Characteristics of patients included in the third supplementary analysis.
RT group (n = 8)
Non-RT group (n = 42)
Standardized difference†
Number or mean (SD)†
(%)†
Number or mean (SD)†
(%)†
Before PSW
After PSW
Age (years)
69.13 (6.66)
65.21 (5.83)
0.624
≈0
Sex
Female
4
(50)
31
(74)
0.506
≈0
Male
4
(50)
11
(26)
Residency
Non-northern
5
(62)
33
(79)
0.358
≈0
Northern
3
(38)
9
(21)
Comorbidity
<1
‡
‡
‡
‡
0.501
≈0
≥1
‡
‡
‡
‡
BMI (kg/m2)
23.53 (3.15)
24.35 (4.33)
0.217
≈0
Social-economic status
Minimum wage or lower
‡
‡
‡
‡
0.285
≈0
Higher
‡
‡
‡
‡
Smoking
No
‡
‡
‡
‡
0.144
≈0
Yes
‡
‡
‡
‡
Clinical T-stage
T1–T2
‡
‡
‡
‡
0.133
≈0
T3–T4
‡
‡
‡
‡
Clinical N-stage
N0–N2
4
(50)
13
(31)
0.133
≈0
N3
4
(50)
29
(69)
Tumor size (mm)
52.38 (22.93)
42.71 (19.87)
0.450
≈0
ECOG PS
0-1
‡
‡
‡
‡
0.501
≈0
2
‡
‡
‡
‡
BMI, body mass index; ECOG PS, eastern cooperative oncology group performance status; PS, propensity score; RT, radiotherapy; SD, standard deviation. †Rounded. ‡The exact numbers are not reported because of a health and welfare data science center (HWDC) database center policy to avoid numbers ≤2 in single cells.